Lemborexant and Daridorexant for the Treatment of Insomnia: An Indirect Comparison Using Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed

Leslie Citrome, MD, MPH; Timothy R. Juday, PhD, MPA; Christie Lundwall, PhD

J Clin Psychiatry 2023;84(6):23m14851

ABSTRACT

Objective: To determine if there are differences in the number needed to treat (NNT), number needed to harm (NNH), and likelihood to be helped or harmed (LHH) between lemborexant and daridorexant and to compare lemborexant with daridorexant indirectly.

Methods: Dichotomous efficacy and tolerability outcomes reported for Phase 3 daridorexant trials (conducted May 29, 2018–May 14, 2020) for months 1 and 3 were identified from published literature and regulatory documents. Analogous data were extracted for lemborexant from Phase 3 studies (conducted May 31, 2016–January 8, 2019). NNT, NNH, and LHH were then calculated.

Results: Lemborexant 5 mg and 10 mg had clinically relevant therapeutic effect sizes, evidenced by most NNT values versus placebo < 10 for Insomnia Severity Index [ISI], subjective total sleep time [sTST], and polysomnography outcomes. NNH values for adverse events (AEs) were > 10, suggesting relative tolerability. Somnolence was the most common AE. Discontinuation rates of lemborexant because of an AE were low, including for somnolence. Efficacy outcomes for daridorexant 25-mg and 50-mg doses pooled resulted in most NNT values versus placebo ≥ 10, with more robust NNT estimates for the 50-mg dose than for the 25-mg dose. Discontinuation rate because of an AE at month 3 was higher for placebo than for daridorexant, rendering favorable LHH calculations. Daridorexant evidenced low rates of somnolence or fatigue.

Conclusions: In Phase 3 trials, the benefit-risk ratios for both lemborexant and daridorexant were favorable as measured by NNT, NNH, and LHH. Indirect comparisons of lemborexant with daridorexant suggest an efficacy advantage for lemborexant and a tolerability advantage for daridorexant.

Clinical Trials Registration: NCT02783729, NCT02952820, NCT03545191, NCT03575104

J Clin Psychiatry 2023;84(6):23m14851

Author affiliations are listed at the end of this article.

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Download Free PDF

References (29)

Rosenberg R, Citrome L, Drake CL. Advances in the treatment of chronic insomnia: a narrative review of new nonpharmacologic and pharmacologic therapies. Neuropsychiatr Dis Treat. 2021;17:2549–2566. PubMed CrossRef
Morin CM, Drake CL, Harvey AG, et al. Insomnia disorder. Nat Rev Dis Primers. 2015;1(1):15026. PubMed CrossRef
Krystal AD, Prather AA, Ashbrook LH. The assessment and management of insomnia: an update. World Psychiatry. 2019;18(3):337–352. PubMed CrossRef
Janto K, Prichard JR, Pusalavidyasagar S. An update on dual orexin receptor antagonists and their potential role in insomnia therapeutics. J Clin Sleep Med. 2018;14(8):1399–1408. PubMed CrossRef
Taylor DJ, Mallory LJ, Lichstein KL, et al. Comorbidity of chronic insomnia with medical problems. Sleep. 2007;30(2):213–218. PubMed CrossRef
Palagini L, Manni R, Aguglia E, et al. Expert opinions and consensus recommendations for the evaluation and management of insomnia in clinical practice: joint statements of five Italian scientific societies. Front Psychiatry. 2020;11:558. PubMed CrossRef
Bathgate CJ, Edinger JD, Krystal AD. Insomnia patients with objective short sleep duration have a blunted response to cognitive behavioral therapy for insomnia. Sleep (Basel). 2017;40(1):zsw012. PubMed
Vgontzas AN, Fernandez-Mendoza J. Insomnia with short sleep duration: nosologic, diagnostic, and treatment implications. Sleep Med Clin. 2013;8(3):309–322. PubMed CrossRef
Liu MT. Current and emerging therapies for insomnia. Am J Manag Care. 2020;26(suppl 4):S85–S90. PubMed CrossRef
Merck and Co Inc. BELSOMRA (suvorexant) tablets, for oral use, C-IV [prescribing information, January 2020]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204569s006lbl.pdf. Accessed November 23, 2022.
Eisai Inc. DAYVIGO (lemborexant) tablets, for oral use, CIV [prescribing information, March 2022]. https://www.dayvigo.com/-/media/Files/DAYVIGO/PDF/prescribing-information.pdf. Accessed November 23, 2022.
Idorsia Pharmaceuticals US Inc. QUVIVIQ (daridorexant) tablets, for oral use, [controlled substance schedule pending] [prescribing information, January 2022]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214985s000lbl.pdf. Accessed October 28, 2022.
Citrome L. Compelling or irrelevant? using number needed to treat can help decide. Acta Psychiatr Scand. 2008;117(6):412–419. PubMed CrossRef
Citrome L, Ketter TA. When does a difference make a difference? interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract. 2013;67(5):407–411. PubMed CrossRef
Citrome L. Number needed to treat and number needed to harm: what are they good for? Eur Neuropsychopharmacol. 2023;68:105–107. PubMed CrossRef
Citrome L, Juday T, Frech F, et al. Lemborexant for the treatment of insomnia: direct and indirect comparisons with other hypnotics using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Clin Psychiatry. 2021;82(4):20m13795. PubMed CrossRef
US FDA. Drug Approval Package: QUVIVIQ, Application Number: 214985. FDA website. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214985Orig1s000TOC.cfm. Approval Date: January 7, 2022. Accessed March 6, 2022.
Mignot E, Mayleben D, Fietze I, et al; investigators. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurol. 2022;21(2):125–139. PubMed CrossRef
Rosenberg R, Murphy P, Zammit G, et al. Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial. JAMA Netw Open. 2019;2(12):e1918254. PubMed CrossRef
Kärppä M, Yardley J, Pinner K, et al. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2. Sleep (Basel). 2020;43(9):zsaa123. PubMed CrossRef
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition. Arlington, VA: American Psychiatric Publishing; 2013.
Bastien CH, Vallières A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001;2(4):297–307. PubMed CrossRef
Vo P, Wen S, Martel M-J, et al. Benefit-risk assessment of erenumab and current migraine prophylactic treatments using the likelihood of being helped or harmed. Cephalalgia. 2019;39(5):608–616. PubMed CrossRef
Citrome L, Sánchez Del Rio M, Dong Y, et al. Benefit–risk assessment of galcanezumab versus placebo for the treatment of episodic and chronic migraine using the metrics of number needed to treat and number needed to harm. Adv Ther. 2021;38(8):4442–4460. PubMed CrossRef
Azeez IA, Del Gallo F, Cristino L, et al. Daily fluctuation of orexin neuron activity and wiring: the challenge of “chronoconnectivity.” Front Pharmacol. 2018;9:1061. PubMed CrossRef
Beuckmann CT, Suzuki M, Ueno T, et al. In vitro and in silico characterization of lemborexant (E2006), a novel dual orexin receptor antagonist. J Pharmacol Exp Ther. 2017;362(2):287–295. PubMed CrossRef
Krause A, Lott D, Brussee JM, et al. Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist. CPT Pharmacometrics Syst Pharmacol. 2023;12(1):74–86. PubMed CrossRef
Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940–947. PubMed CrossRef
De Crescenzo F, D’Alò GL, Ostinelli EG, et al. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. Lancet. 2022;400(10347):170–184. PubMed CrossRef